LYMPHANGIOLEIOMYOMATOSIS
Clinical trials for LYMPHANGIOLEIOMYOMATOSIS explained in plain language.
Never miss a new study
Get alerted when new LYMPHANGIOLEIOMYOMATOSIS trials appear
Sign up with your email to follow new studies for LYMPHANGIOLEIOMYOMATOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail trial aims to tame tough tumors
Disease control OngoingThis early-phase trial tests the safety and best dose of two drugs (bevacizumab and temsirolimus) given alone or with a third drug (valproic acid or cetuximab) in people with advanced cancers or certain non-cancerous but progressive diseases. The goal is to find tolerable doses a…
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:20 UTC
-
Can a PET scan predict drug response in rare lung disease?
Knowledge-focused OngoingThis study explores whether a special PET scan using [11C]acetate can detect early signs that the drug rapamycin is working in people with lymphangioleiomyomatosis (LAM), a rare lung disease. Seven adults with LAM and at least one kidney tumor will receive one or two PET scans ov…
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS
Phase: PHASE1, PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated May 05, 2026 11:53 UTC